Modus Therapeutics Appoints Key Scientific Advisors
STOCKHOLM, SWEDEN – 23 September 2021: Modus Therapeutics Holding AB (“Modus”), a company developing innovative treatments for patients with high unmet medical needs, welcomes a panel of key scientific advisors – Professor Eddie Weitzberg, Professor Lennart Lindbom and Professor Mats Wahlgren from the Karolinska Institutet – who will support the company’s future development strategy for sevuparin for sepsis/septic shock and other conditions where systemic inflammation is involved.Lennart Lindbom is Professor of Physiology at the Department of Physiology and Pharmacology at Karolinska